Iboga Licio US is an independent resource on ibogaine for people researching ibogaine. We exist to bring clear, evidence-focused information about safety, legality, and practical questions to readers without offering medical advice or treatment.
We prioritise clear sourcing and transparent curation. Our editors gather registries, peer-reviewed literature, official guidance and publicly available clinic protocols to summarise what is known, and we note where evidence is limited or contested. When discussing regulatory status we reference primary sources rather than secondary summaries; for example, we consult authoritative policy pages and recognized reference works to support claims about legality and safety standards (Wikipedia's overview of ibogaine provides a concise, citable background) and we align methodological notes with institutional guidance such as that found on the U.S. National Library of Medicine.
Primary peer‑reviewed studies, official regulatory pages, trial registries, and reputable academic summaries form our baseline. We describe methods and limitations so readers can assess confidence and applicability.
Claims are checked against more than one independent source and flagged when evidence is anecdotal, preliminary, or contested. We do not endorse unverified clinical claims or list unvetted treatment offers.
Entries are reviewed periodically; when new high-quality evidence or regulatory changes emerge, we update the relevant pages and note the revision date.
Iboga Licio US organises material around evidence, safety, legality and practical questions related to ibogaine for people researching ibogaine. Content is framed to help readers understand the sources and limits of available information rather than to offer clinical recommendations. Where readers need to explore treatment options, we link to descriptive resources about service models and respectfully note jurisdictional differences; for details on available programs and approaches in other countries, some readers consult third-party directories such as the Canadian treatment listings, for example the registry at ibogainetreatmentcentersincanada.com, while keeping in mind our site does not validate clinics.
People researching ibogaine — whether preparing academic reading, checking safety considerations, or seeking clarity on legal contexts — will find structured summaries, source links, and editorial notes explaining uncertainty and evidence gaps.
Our values guide what we publish and how we label uncertainty.
Iboga Licio US is an independent information resource. It is not a clinic, medical provider, or licensed treatment center, and its content is not medical or legal advice. Readers should consult qualified professionals and primary regulatory sources for treatment or legal decisions; for example, official health guidance and clinical trial registries are commonly used to verify practice standards (ClinicalTrials.gov) and national health libraries provide reliable summaries (U.S. National Library of Medicine).
To return to topical entry points and navigational summaries, see our main pages on the site, starting with the overview available from the site’s front page, or explore contextual resources offered under our Services overview.
If you have a question about how we sourced or vetted a piece, our editorial process is open to scrutiny; we aim to add transparent notes and citations on request. Visit the Contact page to find the appropriate channel for editorial inquiries.